Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent/Refractory Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Study completedNCT00006383
What this trial is testing

Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Inex Pharmaceuticals
Early research (Phase 1)Study completedNCT00126646
What this trial is testing

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 24
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Large-scale testing (Phase 3)Ended earlyNCT00363636
What this trial is testing

Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin's
Biogen 340
Testing effectiveness (Phase 2)UnknownNCT05115409
What this trial is testing

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Who this might be right for
Relapsed or Refractory DLBCL
Sun Yat-sen University 27
Testing effectiveness (Phase 2)Study completedNCT01555541
What this trial is testing

Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large Cell Lymphoma Relapsed/Refractory
C. Babis Andreadis 19
Testing effectiveness (Phase 2)Ended earlyNCT02568683
What this trial is testing

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non-Hodgkin Lymphoma
Gilead Sciences 10
Early research (Phase 1)Looking for participantsNCT07332507
What this trial is testing

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Who this might be right for
Recurrent Plasmablastic LymphomaRefractory Plasmablastic Lymphoma
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT00086944
What this trial is testing

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)Ended earlyNCT00005595
What this trial is testing

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

Who this might be right for
Lymphoma
Northwestern University 2
Early research (Phase 1)Study completedNCT00003005
What this trial is testing

Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
Boston Medical Center 14
Early research (Phase 1)Study completedNCT00686556
What this trial is testing

Total Marrow Irradiation for Refractory Acute Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeMultiple Myeloma
Masonic Cancer Center, University of Minnesota 12
Large-scale testing (Phase 3)Looking for participantsNCT07011056
What this trial is testing

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent and Refractory Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd 390
Testing effectiveness (Phase 2)Study completedNCT00003245
What this trial is testing

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 50
Very early researchLooking for participantsNCT07606937
What this trial is testing

Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

Who this might be right for
Relapsed/Refractory Large B-cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd. 12
Testing effectiveness (Phase 2)Study completedNCT00004145
What this trial is testing

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Chicago 16
Early research (Phase 1)UnknownNCT03599375
What this trial is testing

Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia, B-Cell
jiuwei cui 20
Early research (Phase 1)Study completedNCT00060645
What this trial is testing

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 33
Next Page